{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T03:46:13Z","timestamp":1792035973233,"version":"4.4.0"},"reference-count":38,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","lungcancerjournal.info","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Lung Cancer"],"published-print":{"date-parts":[[2020,6]]},"DOI":"10.1016\/j.lungcan.2020.04.020","type":"journal-article","created":{"date-parts":[[2020,4,24]],"date-time":"2020-04-24T13:35:16Z","timestamp":1587735316000},"page":"40-48","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"special_numbering":"C","title":["Co-occurrence of targetable mutations in Non-small cell lung cancer (NSCLC) patients harboring MAP2K1 mutations"],"prefix":"10.1016","volume":"144","author":[{"given":"Matthias","family":"Scheffler","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Holzem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Kron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucia","family":"Nogova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michaela A.","family":"Ihle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cornelia","family":"von Levetzow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jana","family":"Fassunke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"W\u00f6mpner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabeth","family":"Bitter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophia","family":"Koleczko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana S.Y.","family":"Abdulla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian","family":"Michels","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rieke","family":"Fischer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Riedel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan-Philipp","family":"Weber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theresa","family":"Westphal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrich","family":"Gerigk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jens","family":"Kern","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Britta","family":"Kaminsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Winfried","family":"Randerath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karl-Otto","family":"Kambartel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabine","family":"Merkelbach-Bruse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reinhard","family":"B\u00fcttner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00fcrgen","family":"Wolf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/j.lungcan.2020.04.020_bib0005","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1056\/NEJMoa0810699","article-title":"Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma","volume":"361","author":"Mok","year":"2009","journal-title":"The New England journal of medicine"},{"issue":"3","key":"10.1016\/j.lungcan.2020.04.020_bib0010","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/S1470-2045(11)70393-X","article-title":"Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial","volume":"13","author":"Rosell","year":"2012","journal-title":"The Lancet Oncology"},{"issue":"2","key":"10.1016\/j.lungcan.2020.04.020_bib0015","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/S1470-2045(14)71173-8","article-title":"Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials","volume":"16","author":"Yang","year":"2015","journal-title":"The Lancet Oncology"},{"issue":"25","key":"10.1016\/j.lungcan.2020.04.020_bib0020","doi-asserted-by":"crossref","first-page":"2385","DOI":"10.1056\/NEJMoa1214886","article-title":"Crizotinib versus chemotherapy in advanced ALK-positive lung cancer","volume":"368","author":"Shaw","year":"2013","journal-title":"The New England journal of medicine"},{"issue":"21","key":"10.1016\/j.lungcan.2020.04.020_bib0025","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.1056\/NEJMoa1406766","article-title":"Crizotinib in ROS1-rearranged non-small-cell lung cancer","volume":"371","author":"Shaw","year":"2014","journal-title":"The New England journal of medicine"},{"issue":"2","key":"10.1016\/j.lungcan.2020.04.020_bib0030","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/S1470-2045(15)00488-X","article-title":"Alectinib in ALK-positive, crizotinib-resistant, non-small-cell lung cancer: a single-group, multicentre, phase 2 trial","volume":"17","author":"Shaw","year":"2016","journal-title":"The Lancet Oncology"},{"key":"10.1016\/j.lungcan.2020.04.020_bib0035","doi-asserted-by":"crossref","DOI":"10.18632\/oncotarget.3387","article-title":"ROS1 rearrangements in lung adenocarcinoma: prognostic impact, therapeutic options and genetic variability","author":"Scheffler","year":"2015","journal-title":"Oncotarget"},{"issue":"9","key":"10.1016\/j.lungcan.2020.04.020_bib0040","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1038\/s41568-019-0179-8","article-title":"Co-occurring genomic alterations in non-small-cell lung cancer biology and therapy","volume":"19","author":"Skoulidis","year":"2019","journal-title":"Nature reviews Cancer"},{"issue":"5198","key":"10.1016\/j.lungcan.2020.04.020_bib0045","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1126\/science.7839144","article-title":"Independent human MAP-kinase signal transduction pathways defined by MEK and MKK isoforms","volume":"267","author":"D\u00e9rijard","year":"1995","journal-title":"Science (New York, NY)"},{"issue":"5191","key":"10.1016\/j.lungcan.2020.04.020_bib0050","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1126\/science.7992057","article-title":"Differential activation of ERK and JNK mitogen-activated protein kinases by Raf-1 and MEKK","volume":"266","author":"Minden","year":"1994","journal-title":"Science (New York, NY)"},{"key":"10.1016\/j.lungcan.2020.04.020_bib0055","article-title":"K-ras mutation subtypes in NSCLC and associated co-occuring mutations in other oncogenic pathways","author":"Scheffler","year":"2018","journal-title":"Journal of Thoracic Oncology"},{"issue":"5","key":"10.1016\/j.lungcan.2020.04.020_bib0060","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1158\/2159-8290.CD-17-1452","article-title":"Allele-Specific Mechanisms of Activation of MEK1 Mutants Determine Their Properties","volume":"8","author":"Gao","year":"2018","journal-title":"Cancer discovery"},{"issue":"5","key":"10.1016\/j.lungcan.2020.04.020_bib0065","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1093\/annonc\/mdv072","article-title":"A randomized phase II study of the MEK1\/MEK2 inhibitor trametinib (GSK1120212) compared with docetaxel in KRAS-mutant advanced non-small-cell lung cancer (NSCLC)\u2020","volume":"26","author":"Blumenschein","year":"2015","journal-title":"Annals of oncology : official journal of the European Society for Medical Oncology \/ ESMO"},{"issue":"9","key":"10.1016\/j.lungcan.2020.04.020_bib0070","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1200\/JCO.2014.58.2007","article-title":"Molecular profiling and targeted therapy for advanced thoracic malignancies: a biomarker-derived, multiarm, multihistology phase II basket trial","volume":"33","author":"Lopez-Chavez","year":"2015","journal-title":"Journal of clinical oncology : official journal of the American Society of Clinical Oncology"},{"issue":"7511","key":"10.1016\/j.lungcan.2020.04.020_bib0075","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1038\/nature13385","article-title":"Comprehensive molecular profiling of lung adenocarcinoma","volume":"511","author":"Network","year":"2014","journal-title":"Nature"},{"issue":"8","key":"10.1016\/j.lungcan.2020.04.020_bib0080","first-page":"1493","article-title":"RAF1-MEK1-ERK\/AKT axis may confer NSCLC cell lines resistance to erlotinib","volume":"6","author":"Xu","year":"2013","journal-title":"International journal of clinical and experimental pathology"},{"issue":"6216","key":"10.1016\/j.lungcan.2020.04.020_bib0085","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1126\/science.1254721","article-title":"Patient-derived models of acquired resistance can identify effective drug combinations for cancer","volume":"346","author":"Crystal","year":"2014","journal-title":"Science (New York, NY)"},{"issue":"14","key":"10.1016\/j.lungcan.2020.04.020_bib0090","doi-asserted-by":"crossref","first-page":"3334","DOI":"10.1158\/1078-0432.CCR-17-2452","article-title":"Resistance Mechanisms to Targeted Therapies in ROS1+ and ALK+ Non-small Cell Lung Cancer","volume":"24","author":"McCoach","year":"2018","journal-title":"Clinical cancer research : an official journal of the American Association for Cancer Research"},{"key":"10.1016\/j.lungcan.2020.04.020_bib0095","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.ctrv.2016.12.001","article-title":"Cancer resistance to therapies against the EGFR-RAS-RAF pathway: The role of MEK","volume":"53","author":"Martinelli","year":"2017","journal-title":"Cancer treatment reviews"},{"issue":"8","key":"10.1016\/j.lungcan.2020.04.020_bib0100","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1158\/1078-0432.CCR-14-2124","article-title":"MAP2K1 (MEK1) Mutations Define a Distinct Subset of Lung Adenocarcinoma Associated with Smoking","volume":"21","author":"Arcila","year":"2015","journal-title":"Clinical cancer research : an official journal of the American Association for Cancer Research"},{"issue":"10","key":"10.1016\/j.lungcan.2020.04.020_bib0105","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1001\/jamaoncol.2018.2668","article-title":"Modeled Prognostic Subgroups for Survival and Treatment Outcomes in BRAF V600-Mutated Metastatic Melanoma: Pooled Analysis of 4 Randomized Clinical Trials","volume":"4","author":"Hauschild","year":"2018","journal-title":"JAMA oncology"},{"key":"10.1016\/j.lungcan.2020.04.020_bib0110","doi-asserted-by":"crossref","DOI":"10.1158\/0008-5472.CAN-14-3167","article-title":"Acquired resistance to mutant-selective EGFR inhibitor AZD9291 is associated with increased dependence on RAS signaling in preclinical models","author":"Eberlein","year":"2015","journal-title":"Cancer research"},{"key":"10.1016\/j.lungcan.2020.04.020_bib0115","doi-asserted-by":"crossref","DOI":"10.1158\/1078-0432.CCR-15-1915","article-title":"Heterogeneous mechanisms of primary and acquired resistance to third-generation EGFR inhibitors","author":"Ortiz-Cuaran","year":"2016","journal-title":"Clinical cancer research : an official journal of the American Association for Cancer Research"},{"issue":"1","key":"10.1016\/j.lungcan.2020.04.020_bib0120","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.jmoldx.2010.11.005","article-title":"Detection of KRAS and BRAF mutations in colorectal carcinoma roles for high-sensitivity locked nucleic acid-PCR sequencing and broad-spectrum mass spectrometry genotyping","volume":"13","author":"Arcila","year":"2011","journal-title":"The Journal of molecular diagnostics : JMD"},{"issue":"20","key":"10.1016\/j.lungcan.2020.04.020_bib0125","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1056\/NEJMc1511490","article-title":"Trametinib in Histiocytic Sarcoma with an Activating MAP2K1 (MEK1) Mutation","volume":"378","author":"Gounder","year":"2018","journal-title":"The New England journal of medicine"},{"issue":"16","key":"10.1016\/j.lungcan.2020.04.020_bib0130","doi-asserted-by":"crossref","first-page":"3631","DOI":"10.1158\/1078-0432.CCR-14-2683","article-title":"Broad, Hybrid Capture-Based Next-Generation Sequencing Identifies Actionable Genomic Alterations in Lung Adenocarcinomas Otherwise Negative for Such Alterations by Other Genomic Testing Approaches","volume":"21","author":"Drilon","year":"2015","journal-title":"Clinical cancer research : an official journal of the American Association for Cancer Research"},{"issue":"suppl_3","key":"10.1016\/j.lungcan.2020.04.020_bib0135","doi-asserted-by":"crossref","first-page":"iii25","DOI":"10.1093\/annonc\/mdw303","article-title":"ALK evaluation in the world of multiplex testing: Network Genomic Medicine (NGM): the Cologne model for implementing personalised oncology","volume":"27","author":"Heydt","year":"2016","journal-title":"Annals of oncology : official journal of the European Society for Medical Oncology \/ ESMO"},{"issue":"4","key":"10.1016\/j.lungcan.2020.04.020_bib0140","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1158\/1078-0432.CCR-14-0450","article-title":"MET amplification status in therapy-na\u00efve adeno- and squamous cell carcinomas of the lung","volume":"21","author":"Schildhaus","year":"2015","journal-title":"Clinical cancer research : an official journal of the American Association for Cancer Research"},{"issue":"1","key":"10.1016\/j.lungcan.2020.04.020_bib0145","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.jtho.2015.09.016","article-title":"Clinicopathological Characteristics of RET Rearranged Lung Cancer in European Patients","volume":"11","author":"Michels","year":"2016","journal-title":"Journal of Thoracic Oncology"},{"issue":"2","key":"10.1016\/j.lungcan.2020.04.020_bib0150","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"European journal of cancer (Oxford, England : 1990)"},{"issue":"1","key":"10.1016\/j.lungcan.2020.04.020_bib0155","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/PO.17.00011","article-title":"OncoKB: A Precision Oncology Knowledge Base","volume":"2017","author":"Chakravarty","year":"2017","journal-title":"JCO Precision Oncology"},{"issue":"269","key":"10.1016\/j.lungcan.2020.04.020_bib0160","doi-asserted-by":"crossref","DOI":"10.1126\/scisignal.2004088","article-title":"Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal","volume":"6","author":"Gao","year":"2013","journal-title":"Science signaling"},{"issue":"5","key":"10.1016\/j.lungcan.2020.04.020_bib0165","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1158\/2159-8290.CD-12-0095","article-title":"The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data","volume":"2","author":"Cerami","year":"2012","journal-title":"Cancer discovery"},{"issue":"10","key":"10.1016\/j.lungcan.2020.04.020_bib0170","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1038\/modpathol.2016.117","article-title":"Harmonized PD-L1 immunohistochemistry for pulmonary squamous-cell and adenocarcinomas","volume":"29","author":"Scheel","year":"2016","journal-title":"Modern Pathol"},{"issue":"13","key":"10.1016\/j.lungcan.2020.04.020_bib0175","doi-asserted-by":"crossref","first-page":"3087","DOI":"10.1158\/1078-0432.CCR-17-3416","article-title":"Clinical and Pathological Characteristics of KEAP1- and NFE2L2-Mutated Non-Small Cell Lung Carcinoma (NSCLC)","volume":"24","author":"Frank","year":"2018","journal-title":"Clinical cancer research : an official journal of the American Association for Cancer Research"},{"key":"10.1016\/j.lungcan.2020.04.020_bib0180","doi-asserted-by":"crossref","DOI":"10.1158\/2159-8290.CD-14-1236","article-title":"Co-occurring genomic alterations define major subsets of KRAS - mutant lung adenocarcinoma with distinct biology, immune profiles, and therapeutic vulnerabilities","author":"Skoulidis","year":"2015","journal-title":"Cancer discovery"},{"issue":"15_suppl","key":"10.1016\/j.lungcan.2020.04.020_bib0185","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2019.37.15_suppl.102","article-title":"Association of STK11\/LKB1 genomic alterations with lack of benefit from the addition of pembrolizumab to platinum doublet chemotherapy in non-squamous non-small cell lung cancer","volume":"37","author":"Skoulidis","year":"2019","journal-title":"Journal of Clinical Oncology"},{"issue":"3","key":"10.1016\/j.lungcan.2020.04.020_bib0190","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1007\/s00292-019-0605-4","article-title":"Das nationale Netzwerk Genomische Medizin (nNGM)","volume":"40","author":"Medizin","year":"2019","journal-title":"Der Pathologe"}],"container-title":["Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500220303913?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500220303913?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T12:38:43Z","timestamp":1759235923000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169500220303913"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6]]},"references-count":38,"alternative-id":["S0169500220303913"],"URL":"https:\/\/doi.org\/10.1016\/j.lungcan.2020.04.020","relation":{},"ISSN":["0169-5002"],"issn-type":[{"value":"0169-5002","type":"print"}],"subject":[],"published":{"date-parts":[[2020,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Co-occurrence of targetable mutations in Non-small cell lung cancer (NSCLC) patients harboring MAP2K1 mutations","name":"articletitle","label":"Article Title"},{"value":"Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lungcan.2020.04.020","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}